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Research Article
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HIV infection is associated with the increased risk of cardiovascular disease (CVD), even in
patients successfully treated with the combination antiretroviral therapy (cART). However,
the relationship between HIV, cART, and pathogenesis of CVD remains controversial. In the
present study, we evaluated the carotid intima–media thickness (CIMT), a surrogate marker
of atherosclerosis, in HIV-infected subjects receiving or not receiving cART. One hundred
nine newly diagnosed HIV-infected subjects and one hundred nine uninfected age-matched
controls (all males) without the history of CVD, hypertension, or diabetes were recruited
into the present study. Cross-sectional analysis at baseline (BL) showed significantly increased levels of triglycerides (TG) and decreased levels of high-density lipoprotein (HDL) in
HIV-infected subjects, indicating that these risk factors for CVD appeared during the undiagnosed period of HIV infection. Nevertheless, no differences in CIMT were detected between
the groups, suggesting that these risk factors were yet to be translated into the clinical
disease. The prospective arm of the study, which included 37 HIV-infected and 23 uninfected subjects, showed higher CIMT increase in HIV-infected group than in control group
(P=0.0063). This difference was significant for both cART-treated (P=0.0066) and untreated
(P=0.0246) subgroups relative to the uninfected subjects, but no difference was found between the HIV-infected subgroups. These results suggest that cART does not reverse the
HIV-induced increase of CIMT. The present study demonstrates that the progression of
atherosclerosis is accelerated in HIV-infected subjects regardless of treatment.
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Introduction of combination antiretroviral treatment (cART) of HIV infection has dramatically reduced
mortality and increased the lifespan of HIV-infected subjects. However, co-morbidities that are not directly related to immunodeficiency persist even in the subjects with undetectable viral load in the blood
[1]. One such co-morbidity is atherosclerosis and cardiovascular disease (CVD), which has become the
major cause of morbidity and mortality of HIV-infected subjects [2]. It is believed that HIV infection
and/or its treatment (cART) are associated with the elevated risk of development of atherosclerosis and
consequently with increased prevalence of acute and chronic cardiovascular events. However, the contribution of each of these two factors (infection and treatment) to disease pathogenesis remains a debatable
issue.

c 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution

License 4.0 (CC BY).
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Early generations of antiretroviral regimens, especially those that included protease inhibitors (PI), were associated with dyslipidemia revealed by the high levels of low-density lipoprotein (LDL) and triglycerides (TG) and low
high-density lipoprotein (HDL) [3], and may have had other, dyslipidemia-unrelated, pro-atherogenic effects [4,5].
HIV-infected subjects treated with PI-containing cART showed higher prevalence of carotid lesions compared with
PI-naive patients or uninfected controls [6]. Current cART regimens, however, are less likely to cause elevation of LDL
and TG [7,8], presumably diminishing the pro-atherogenic effects of these treatments. Nevertheless, HIV-associated
dyslipidemia is not eliminated in the modern era, as low levels of HDL, a key atheroprotective lipoprotein, persist
in both treated and untreated patients [9]. We [10] and others [11] suggested that HIV infection itself, rather than
antiretroviral regimens, may be the main contributor to dyslipidemia and elevated risk of atherosclerosis. Indeed, in
vitro and in vivo studies revealed the inhibitory effect of HIV protein Nef on cellular cholesterol transporter ABCA1
and ABCA1-dependent reverse cholesterol transport [12,13], the key step in HDL formation. However, clinical evidence to support the direct role of HIV in pathogenesis of atherosclerosis is inconsistent.
Several studies that demonstrated an increased risk of atherosclerosis in HIV patients [14-17] were cross-sectional
or retrospective by design, thus providing only association-based conclusion. A 1-year prospective study reported
a faster increase in carotid intima–media thickness (CIMT) in HIV patients on PI-containing regimens compared
with HIV-negative individuals, and concluded that HIV infection is an independent risk factor of atherosclerosis [18]. In contrast, our 1-year prospective study did not reveal the CIMT progression in cART-treated or untreated HIV-infected subjects during this short period of time [19]. Another study, a 3-year follow-up of a cohort
of HIV-infected subjects (without a control group), demonstrated the progression of CIMT at a higher rate than published values for uninfected subjects, but concluded that ‘traditional cardiovascular risk factors remain the strongest
determinants of carotid and coronary atherosclerotic disease progression in HIV-infected patients’ [20]. Other studies demonstrated no impact of HIV infection or non-PI treatment regimens on surrogate markers of atherosclerosis
when adjusted for conventional risk factors [21-23], including the two prospective studies [24,25].
In the present study, we assessed atherosclerosis in a cross-sectional study of 109 HIV-infected subjects and 109
uninfected controls, using a surrogate measure of atherosclerosis, CIMT, and followed up some of the participants
in these groups over 2 years. We compared groups of HIV-infected patients who remained untreated, those that
commenced treatment with cART, and HIV-negative subjects.

Methods
Study design and subjects
A 2-year, open-label, case–control, observational study was aimed to provide the prospective data on the progression
of atherosclerosis in HIV-infected individuals and the effect of antiretroviral therapy on the dynamics of the CIMT
of common carotid arteries as a quantitative surrogate measure of atherosclerosis. The present study was kept in accordance with the Helsinki Declaration of 1975 as revised in 1983. Written informed consent was obtained from each
patient included in the study. It was approved by the local ethics committee of the Institute for Atherosclerosis Research, Skolkovo Innovation Center, Moscow, Russia (approval #1-15.10.09). The 109 newly diagnosed HIV-infected
male subjects were enrolled at the Moscow City Centre for AIDS Prevention and Control, the Moscow City Health
Department. Uninfected male participants (109 subjects) were recruited from the patients attending Moscow municipal outpatient clinic No. 202. All study participants were aged between 22 and 60 years. The exclusion criteria were:
history of hypertension, diabetes, CVD, familial hypercholesterolemia, liver dysfunction, body mass index over 27
kg/m2 . In addition, administration of lipid-lowering medications for 6 months before the enrollment and during the
follow-up period was also a criterion for exclusion.

Measurements
Lipid parameters were measured using the standard laboratory procedures at baseline (BL). Viral load was measured
by the quantitative RT-PCR and CD4 T-cell counts – by flow cytometry. Viral load and CD4 T cells were also measured
1 year after the inclusion in the prospective study. The examination of carotid atherosclerosis by IMT was performed
using high-resolution B-mode ultrasonography with a linear vascular 7.5 MHz probe on SonoScape S SI-1000 scanner (China). The examination was carried out in a supine position after a 15-min rest and included the scanning
of the left and right carotid arteries and the carotid sinus area, keeping a focus on the rear wall of the artery in the
three fixed projections – anterolateral, lateral, and posterolateral. Measurements were made at the site of the common
carotid artery 10 mm long, opposite to the origin of the carotid sinus. The thickness of the intima–media layer of the
posterior wall of the common carotid artery was defined as the distance from the leading edge of the first echogenic
zone to the leading edge of the second echogenic zone. The mean of the three measurements (in the anterolateral,
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Table 1 Clinical and laboratory characteristics of study participants
HIV-infected, n=109

Uninfected, n=109

P-value

Age, years

37.6 (8.5)

36.4 (7.4)

0.24

Systolic BP, mmHg

128 (17)

128 (15)

0.95

Diastolic BP, mmHg

83 (10)

82 (11)

0.39

Smokers, %

51 (5)

35 (8)

0.08

Family history of CVD, %

48 (5)

53 (8)

0.64

ALT, mmol/l

40.3 (37.8)

35.1 (27.0)

0.61

AST, mmol/l

34.3 (30.9)

27.2 (12.2)

0.34

Blood glucose, mmol/l

5.2 (1.00)

5.2 (0.95)

0.81
0.12

Total cholesterol, mmol/l

5.2 (1.5)

5.5 (1.0)

TGs, mmol/l

2.1 (1.7)

1.5 (1.0)

0.007

HDL-C, mmol/l

1.1 (0.3)

1.4 (0.4)

0.001

LDL-C, mmol/l

3.3 (0.9)

3.5 (0.9)

0.27

CIMT, mm

0.645 (0.097)

0.637 (0.099)

0.54

CD4+ , cells/ml

439 (261)

Viral load, copies/ml

51; 1602; 26075

Mean (S.D.) values are shown for all parameters except viral load, for which the 25% percentile, median, and 75% percentile are shown. No signiﬁcant
correlation has been detected between CIMT and any of the measured parameters. BP, blood pressure; ALT, alanine aminotransferase; AST, aspartate
aminotransferase.

lateral, and posterolateral projections) was taken as an integral estimate of CIMT [26]. Scanning was performed by
the trained sonographers, unaware of the clinical data. Intima–media thickness measurements were made by the independent certified reader in a blinded manner. IMT measurements were performed by dedicated computer software
for IMT analysis, M’Ath (France), which allowed a semiautomatic edge detection of the two echogenic lines defining
the boundaries of the intima plus media arterial layers. The use of this program eliminated the errors in measurements
that can be made by a technician and provided the necessary quality control. Reproducibility of IMT measurements
by this software was assessed according to the protocol of IMPROVE study [27]. The ultrasound examinations of
carotid arteries were performed at the BL and at 2 years of follow-up.

Statistical analysis

Results were expressed as mean CIMT +
− S.D. (mm) or as median with interquartile range (IQR). GraphPad Prism 7.0
software was used for statistical analysis. Significance of differences between the groups was evaluated using unpaired
Student’s t test or Mann–Whitney test, with P<0.05 considered significant. Comparison of several groups was done
by ANOVA, with Tukey post-hoc analysis.

Results and discussion
In both HIV-infected and uninfected groups, 38% of the study participants smoked, 37% consumed alcohol regularly,
and 48% had family history of CVD. Study participants were characterized by normal values of liver tests (ALT: 40 +
−
38 mmol/l and AST: 34 +
− 31 mmol/l) and normal blood glucose level. No significant differences between the groups
were found at BL in blood pressure, total cholesterol, and LDL cholesterol (LDL-C) (Table 1). However, HIV-infected
group had significantly lower levels of HDL cholesterol (HDL-C) than uninfected group (respective mean +
− S.D. of
+
+
1.12 +
0.26
compared
with
1.37
0.41
mmol/l,
P=0.001)
and
higher
levels
of
TG
(respective
mean
S.D.
of 2.12 +
−
−
−
−
mmol/l,
P=0.009)
(Table
1).
High
TG
and
low
HDL
are
the
characteristic
risk
factors
1.70 compared with 1.49 +
0.94
−
of atherosclerosis associated with HIV infection [3]. However, while there was a significant negative correlation between TG and HDL-C levels (Pearson correlation coefficient: −0.320, P=0.0008), no correlation was found between
CIMT and HDL-C or TG levels, suggesting that these lipids did not significantly contribute to atherosclerosis in this
cohort. In fact, CIMT did not significantly correlate with any of the tested parameters. The only borderline correlation
(Pearson r = 0.126, P=0.064) was between CIMT and the number of cigarette packs (20 cigarettes per pack) smoked
per week.
The subjects recruited for our study were newly diagnosed with HIV infection, but the actual duration of the infection prior to the diagnosis has not been established. Interestingly, no significant difference between the groups was
found at BL in CIMT (Table 1), a surrogate marker of subclinical atherosclerosis [17,28]. This result suggests that the
c 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 1. Two-year CIMT increase in HIV-infected and uninfected subjects

(A) An increase in CIMT during the 2-year follow-up is compared between HIV-infected (both cART-treated and untreated, n=36)
and uninfected (control, n=23) subjects. The plot shows individual values and mean +
− S.D. Two-tailed P-value was calculated
by Student’s t test. (B) Analysis of CIMT at BL and 2-year time point (2 y) for HIV-infected cART-treated (n=25) and untreated
(n=11) groups, and uninfected (control) group (n=23). (C) Whisker plot shows median and minimum to maximum range for CIMT
change during the 2-year observation period in groups of control (uninfected) subjects (n=23), untreated HIV-infected patients (HIV,
n=11), and cART-treated patients (HIV + cART, n=25). Two-tailed P-values were calculated by Student’s t test. (D) CIMT increase is
compared between subgroups of PI-treated (n=9), NNRTI-treated (n=16), and untreated (n=11) HIV-infected subjects. Analysis by
ANOVA revealed no statistically significant differences between the groups. NNRTI, non-nucleoside reverse transcriptase inhibitor.

duration of undiagnosed infection in the subjects recruited for the present study was insufficient to translate the increased risk factors into a disease, which is consistent with lack of CIMT progression in newly diagnosed HIV-infected
subjects (cART-treated or untreated) during a 1-year observation period reported in our previous study [19]. Deterioration of cardiovascular conditions (ultrasonographic data, FMD, inflammation, and cytokine markers) reported
previously in treatment-naı̈ve subjects [29] probably occurred after a longer period of uncontrolled infection.
Two years after inclusion in the study, the participants underwent ultrasound re-examination of carotid arteries
to determine the dynamics of CIMT changes; due to participants’ high dropout rate, only 36 HIV-infected and 23
uninfected subjects completed a 2-year study. Of note, calculation of the sample size for the differences in primary
end point, CIMT, to achieve power greater than 0.8 with P-value less than 0.05 and expected coefficient of variability
of 100%, aiming to detect the minimal physiologically relevant difference in CIMT of 50%, gave a minimal sample
size of 22 subjects. The analysis demonstrated a significantly higher CIMT increase in the HIV-infected group (0.056
+
− 0.060 mm) relative to the uninfected controls (0.018 +
− 0.027 mm) (Figure 1A). To evaluate the effect of cART on
CIMT progression, the HIV-infected group was divided in two subgroups; placing subjects who initiated cART (25
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Table 2 BL characteristics of the 2-year prospective study participants
Group 1, HIV+ , cART− , n=11

Group 2, HIV+ , cART+ , n=25

Group 3, uninfected n=23

Age, years

38 (6)

39 (7)

39 (8)

Systolic BP, mmHg

123 (13)

127 (17)

127 (12)

Diastolic BP, mmHg

80 (10)

82 (10)

80 (9)

Total cholesterol, mmol/l

5.1 (1.5)

5.6 (1.9)

5.6 (0.9)

Triglyicerides, mmol/l

2.3 (1.3)

2.3 (1.6)

2.4 (0.6)

HDL-C, mmol/l

1.2 (0.4)

1.1 (0.2)*

1.5 (0.5)

LDL-C, mmol/l

2.8 (0.8)

3.5 (1.1)

3.6 (0.9)

CIMT, mm

0.649 (0.053)

0.646 (0.122)

0.646 (0.112)

CD4, cells/ml

460 (177)

547 (261)

Viral load, copies/ml

40022 (44361)

226555 (624632)

Mean (S.D.) values are shown for all parameters. *P=0.0006 vs group 3.

subjects) into Group 2, and those who remained cART-naive during the 2-year period – in Group 1 (11 subjects). Of
note, according to the Russian National Clinical Recommendations on HIV Diagnostic and Treatment in 2014, when
the present study was initiated, the antiretroviral treatment had to be initiated in all the patients with CD4+ T cell levels
below 350 per μl regardless of HIV load (in 2015, it became 500 cells/μl). For patients with CD4+ T-cell levels above
those limits, attending physicians decided whether to initiate the treatment. Group 3 (23 subjects) was uninfected
controls. Such division compromised the power of analysis, but provided the trends that can be pursued in future
studies. BL characteristics for the groups involved in this subanalysis of prospective study are shown in Table 2. Of
note, subjects initiating ART tended to have higher viral load at BL than subjects that remained drug-free during the
2-year observation period, justifying the treatment decision. The only statistically significant BL difference between
the groups was the level of HDL-C, which was much lower in the group initiating cART (group 2) than in control
(uninfected) group 3 (P=0.0006). This is consistent with the previously observed effect of HIV infection on HDL-C
level and was likely due to a direct influence of HIV on cholesterol efflux and reverse cholesterol transport [9,13].
BL HDL levels in the group that remained cART free were also low, but the difference did not reach the statistical
significance (P=0.09). This was likely due to the lower viral load in this subgroup of subjects (see Table 2). Again, no
differences in CIMT between the groups were found, consistent with the analysis of total recruited population (Table
1). Unfortunately, follow-up measurements of these clinical parameters at the 2-year time point were not available.
However, given that no significant correlation was found between CIMT and any of the measured clinical parameters
(Table 1), it appeared unlikely that the changes in these parameters could explain differences in CIMT progression
(see below).
Analysis of CIMT dynamics revealed a significant increase in median CIMT values after 2 years in all the three
groups, calculated by paired t test (P=0.001 for untreated HIV-infected group, P=0.007 for treated HIV-infected
group, and P=0.004 for the control group, Figure 1B). For pairwise comparisons between the groups, we used unpaired t test. The CIMT increase in both HIV-infected groups (cART-treated and untreated) were larger than in the
control group, and the differences were statistically significant (P=0.025 for the untreated HIV-infected group and
P=0.005 for the treated group, Figure 1C). No statistically significant difference in CIMT increase was observed between untreated and cART-treated HIV-infected groups (P=0.677). These results indicate that during the 2 years
of observation, atherosclerosis progressed faster in both cART-treated and untreated HIV-infected subjects than in
uninfected controls. They also suggest that cART does not slow down the progression of atherosclerosis. The last
result is somewhat surprising, but is consistent with previously reported lack of correlation between HIV viral load
and atherosclerosis [30,31] and increased risk of atherosclerosis in cART-treated subjects (reviewed in [32]).
Previous studies suggested that the PI-based cART may have pro-atherogenic effect by inducing dyslipidemia [3].
We therefore compared the CIMT increase between the subjects receiving the PI-based cART and those receiving
the NNRTI-based treatment (relevant clinical data presented in Table 3). Of note, while in most subjects viral loads
were greatly reduced after 2 years of treatment, in most cases to undetectable levels, in two NNRTI-treated subjects
(#52 and #60) viral loads were unusually high at a 2-year time point (Table 3). Given that CD4+ T-cell counts in these
patients were relatively high, it is likely that observed viremia was due to missed medication rather than emergence
of drug-resistant virus. We also included a group of untreated HIV-infected subjects in this comparison. Results
presented in Figure 1D demonstrate that the CIMT increase was very similar in both cART-treated subgroups, with
no statistically significant difference being detected. Moreover, similar to the combined cART-treated group, which
c 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 3 cART composition and clinical data for HIV-infected subjects completing the 2-year study
CD4+ T cells
after 12
months
(cells/μl)

HIV VL after
12 months
(copies/ml)

CIMT (mm)
after 2 years
−0.044

Subject

Drug

cART

CD4+ T cells
at diagnosis
(cells/μl)

30

PI

Lamividine/Abacavir, Atazanavir

1298

20

1139

40

35

PI

Lamividine, Didanosine, Atazanavir

317

2085

49

513

−0.011

39

PI

Lamividine/Zidovudine, Nelﬁnavir

34

1818033

244

289

0.157

45

PI

Abacavir, Didanosine, Lopinavir/Ritonavir

250

40

412

20

0.109

53

PI

Lamividine/Zidovudine,
Darunavir/Ritonavir

159

20

227

31

0.074

72

PI

Lamividine/Abacavir, Atazanavir

816

20

732

20

0.067

75

PI

Lamividine/Abacavir, Darunavir/Ritonavir

627

68

657

99

0.016

77

PI

Lamividine/Abacavir, Darunavir/Ritonavir

302

20

332

20

0.047

89

PI

Lamividine/Zidovudine, Atazanavir

381

111541

286

40

0.017

3

NNRTI

Lamividine/Abacavir, Evaﬁrenz

432

20

397

20

0.006

HIV VL at
diagnosis
(copies/ml)

9

NNRTI

Lamividine/Abacavir, Evaﬁrenz

837

20

709

20

−0.058

12

NNRTI

Lamividine/Zidovudine, Evaﬁrenz

899

40

685

20

0.069

14

NNRTI

Lamividine/Zidovudine, Evaﬁrenz

952

20

837

20

0.122

15

NNRTI

Lamividine/Abacavir, Evaﬁrenz

729

20

829

20

0.021

16

NNRTI

Lamividine/Abacavir, Evaﬁrenz

454

20

449

20

0.108

20

NNRTI

Lamividine/Zidovudine, Nevirapine

427

20

467

20

0.077

41

NNRTI

Lamividine/Zidovudine, Etravirine

763

20

770

40

0.036

44

NNRTI

Lamividine/Abacavir, Nevirapine

1002

20

952

20

0.107

50

NNRTI

Lamividine/Zidovudine, Evaﬁrenz

32

20

571

40

−0.023

52

NNRTI

Lamividine, Raltegravir, Etravirine

745

20

437

16854

0.216

60

NNRTI

Lamividine/Zidovudine, Etravirine

396

23367

500

14959

0.038

61

NNRTI

Lamividine/Zidovudine, Evaﬁrenz

252

20

252

40

0.065

64

NNRTI

Lamividine/Abacavir, Evaﬁrenz

326

20

491

20

0.145

73

NNRTI

Lamividine/Zidovudine, Nevirapine

252

20

315

20

0.008

78

NNRTI

Lamividine/Abacavir, Evaﬁrenz

811

20

953

20

0.036

Undetectable viral loads were imputed as 20.

did not differ from untreated HIV-infected subgroup (Figure 1C), no significant differences in CIMT increase were
detected between untreated (medianCIMT = 0.028 mm, IQR: 0.017–0.076) and PI-treated (medianCIMT = 0.057
mm, IQR −0.004–0.087), or NNRTI-treated (medianCIMT = 0.052 mm, IQR: 0.011–0.108) subgroups, although
the CIMT increase appeared to be smaller in untreated subjects. This result suggests that PI-based regimen used in
the present study does not have any disadvantage in terms of atherosclerosis relative to NNRTI-based regimen. The
sample size in this analysis was small (9 PI-treated and 16 NNRTI-treated subjects, Table 3), so these results need
further verification.
No statistically significant correlation between CIMT increase at a 2-year time point and viral load or CD4 T-cell
count at BL or at 1-year time point could be found in cART-treated or untreated subjects. Moreover, no significant
difference in CIMT change was found between untreated HIV-infected subjects with viral load below the median
and those with viral load above the median (not shown). Although, the small number of untreated subjects (n=11)
precludes reliable conclusion, it appears that viral load does not have a major impact on CIMT increase, consistent
with the previous reports [30,31]. In view of previously reported contradictory findings regarding the role of HIV
replication in atherosclerosis progression [21-25], it seems reasonable to conclude that the key factor(s) driving progression of atherosclerosis in HIV-infected patients is not virus replication per se or immune deficiency. It is more
likely that virus-related factors produced during untreated HIV infection, as well as during cART treatment, are the
major contributors to atherosclerosis. Such factors include HIV protein Nef, which is released from HIV-infected
cells even when virus replication had been suppressed by cART [33], and is known to have pro-atherogenic activity
[12,34]. Another such factor is persistent inflammation, which does not subside upon HIV suppression [35] and has
a well-established pro-atherogenic effect [36]. These factors have not been analyzed in the present study, so their role
remains speculative.
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The main limitation of the present study is the small number of subjects completing the 2-year prospective observation period. This was due to high dropout rate, in part owing to the fact that no monetary incentives were offered
to the participants. Also, a number of subjects in the untreated group have initiated treatment with cART during
the observation period, excluding them from the study. Despite this limitation, analysis performed in the present
study supports an important conclusion that atherosclerosis progression is accelerated in HIV-infected subjects, and
this acceleration appears to be similar in patients treated and untreated with cART. This outcome apparently contradicts our previously published report [19], which did not find atherosclerosis progression in HIV-infected subjects
in a 1-year prospective study. A possible explanation may be that CIMT changes occurring in 1 year were too small
to be detected, especially given that subjects in our 1-year study were recruited in Australia and had substantially
lower viral load (and probably other virus-related pro-atherogenic factors described above, such as circulating Nef
and inflammation) than subjects in the present study (mean BL levels were under 1 × 105 copies/ml for Australian
cohort and approximately 3 × 105 for the Russian patients). Faster progression of atherosclerosis detected by CIMT
changes in HIV-infected subjects than in uninfected controls is consistent with the results of cross-sectional studies
that reported higher CIMT in HIV-infected cohorts [15-17]. Our study did not reveal differences in CIMT progression between cART-treated and untreated groups, similar to another 2-year prospective study that also did not find
statistically significant differences between these groups [37]. An interesting observation of our study is the lack of
correlation between CIMT progression and viral load or CD4 T-cell counts, even in untreated group, suggesting that
other factors, such as Nef and inflammation, may drive atherosclerosis progression in HIV-infected subjects. Overall,
the present study supports the notion that HIV infection is an independent risk factor for atherosclerosis.
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